Core Insights - Fuxiang Pharmaceutical (300497.SZ) released its Q3 2025 report on October 28, 2025, indicating a total of 6 institutional investors holding shares, amounting to 34.4275 million shares, which represents 6.39% of the total share capital [1] Institutional Holdings - The institutional investors include Qingdao Hengze Rui Fund Management Co., Ltd., Jingdezhen Fuxiang Investment Co., Ltd., Jingdezhen Guokong Financial Development Co., Ltd., Guangzhou Fengshen Automotive Investment Group Co., Ltd., CITIC Jiantou Securities Co., Ltd., and Gongqingcheng Yunfeng Asset Management Co., Ltd. - Yunfeng Value No. 5 Securities Investment Private Fund [1] - The total institutional holding percentage decreased by 1.97 percentage points compared to the previous quarter [1] Public Fund Disclosures - In this period, 27 public funds were not disclosed compared to the previous quarter, including funds such as China Merchants Medical Health Industry Stock, China Merchants Quality Growth Mixed A, China Merchants Frontier Medical Care Stock A, China Merchants Innovation Growth Mixed A, and Bosera Huixing Return One-Year Holding Period Mixed [1]

Core Viewpoint - Fuxiang Pharmaceutical (300497.SZ) reported a significant decline in revenue and net profit for the first three quarters of 2025, indicating potential challenges in its financial performance [1] Financial Performance - The company achieved an operating revenue of 769 million yuan, representing a year-on-year decrease of 21.24% [1] - The net profit attributable to shareholders of the listed company was -62.75 million yuan, indicating a loss [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -88.99 million yuan [1] - The basic earnings per share were -0.12 yuan [1]

Group 1 - The core point of the article is that Fuxiang Pharmaceutical (SZ 300497) held its fifth board meeting on October 27, 2025, to review the Q3 2025 report and other documents [1] - For the year 2024, the revenue composition of Fuxiang Pharmaceutical is as follows: 77.94% from pharmaceutical manufacturing, 21.45% from lithium battery electrolyte additives, and 0.61% from CDMO [1] - As of the report, Fuxiang Pharmaceutical has a market capitalization of 5.4 billion yuan [1]

Group 1 - The core viewpoint of the news is that Fuxiang Pharmaceutical reported a significant decline in revenue and incurred a net loss in the third quarter of 2025 [1] - For the first three quarters of 2025, the company's revenue was approximately 769 million yuan, representing a year-on-year decrease of 21.24% [1] - The net profit attributable to shareholders of the listed company was a loss of approximately 62.75 million yuan, with basic earnings per share showing a loss of 0.12 yuan [1] Group 2 - As of the report, Fuxiang Pharmaceutical has a market capitalization of 5.4 billion yuan [2]

江西富祥药业股份有限公司 证券代码：300497 证券简称：富祥药业 公告编号：2025-068 2025年第三季度报告披露提示性公告 江西富祥药业股份有限公司 董事会 2025 年 10 月 27 日 江西富祥药业股份有限公司2025年第三季度报告将于2025年10月28日在中国证 监会指定的创业板信息披露网站巨潮资讯网（http://www.cninfo.com.cn）上披露，敬 请投资者注意查阅。 特此公告。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 ...

Core Insights - The company reported a third-quarter revenue of 255 million, representing a decline of 13.51% [1] - The net profit for the third quarter was a loss of 55.84 million, down 40.96% [1] - For the first three quarters, the total revenue was 769 million, a decrease of 21.24% [1] - The net profit for the first three quarters was a loss of 62.75 million, showing a slight decline of 1.09% [1]

证券代码：300497 证券简称：富祥药业 公告编号：2025-067 江西富祥药业股份有限公司 第五届董事会第三次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 一、董事会会议召开情况 江西富祥药业股份有限公司（以下简称"公司"）第五届董事会第三次会议于 2025 年 10 月 24 日以电子邮件等方式通知全体董事，并于 2025 年 10 月 27 日以现场及通 讯的方式在景德镇市昌江区鱼丽工业区 2 号公司三楼会议室举行。 会议应出席董事 7 人，实际出席的董事 7 人，其中董事包建华先生、JIZU JOHN CHENG（程健祖）先生、刘洪先生、陈祥强先生、计小青女士以通讯表决方式出席 会议。会议由董事长包建华主持，公司高管列席会议。会议召开和表决程序符合《中 华人民共和国公司法》等法律、法规及本公司章程的有关规定，合法有效。 本议案已经董事会审计委员会审议通过。 特此公告。 江西富祥药业股份有限公司 董事会 2025 年 10 月 27 日 二、董事会会议审议情况 经与会董事审议，通过如下决议： （一）审议通过《2025 年第三季度报告》 ...

Financial Performance - The company's revenue for the third quarter was ¥254,677,075.45, a decrease of 13.51% compared to the same period last year[4] - The net profit attributable to shareholders was -¥55,840,375.42, down 40.96% year-on-year[4] - The net cash flow from operating activities was ¥28,885,723.09, reflecting a significant decline of 80.79% compared to the previous year[4] - Total operating revenue for the current period was CNY 769,351,135.51, a decrease from CNY 976,875,468.35 in the previous period, indicating a decline of approximately 21.2%[24] - Net profit for the current period was approximately -¥67.68 million, compared to -¥69.21 million in the previous period, showing an improvement of about 2.2%[26] - The company's basic earnings per share were -¥0.10, a decrease of 42.86% year-on-year[4] - The basic and diluted earnings per share remained at -¥0.12, unchanged from the previous period[26] Assets and Liabilities - Total assets at the end of the reporting period were ¥4,437,899,038.97, a decrease of 2.18% from the end of the previous year[4] - The company's total current assets decreased from CNY 1,681,023,406.22 to CNY 1,524,371,914.03, a reduction of about 9.3%[20] - The company's total liabilities decreased from CNY 2,359,938,793.22 to CNY 2,269,949,195.38, reflecting a decline of approximately 3.8%[22] - The company's long-term borrowings increased from CNY 736,484,000.00 to CNY 829,474,000.00, an increase of about 12.6%[22] - The company's retained earnings decreased from CNY 264,515,944.43 to CNY 201,764,418.36, a decline of approximately 23.7%[22] Cash Flow - The company's cash and cash equivalents decreased from CNY 695,350,502.08 to CNY 632,736,892.59, a drop of about 9.0%[20] - Cash flow from operating activities generated a net amount of ¥28.89 million, down from ¥150.36 million in the previous period, indicating a decline of approximately 80.8%[28] - Cash flow from investing activities resulted in a net outflow of approximately -¥192.72 million, compared to -¥131.58 million in the previous period, reflecting an increase in outflow of about 46.5%[29] - Cash flow from financing activities yielded a net inflow of ¥157.11 million, contrasting with a net outflow of -¥13.25 million in the previous period, marking a significant turnaround[30] - The net cash and cash equivalents at the end of the period stood at ¥542.60 million, a decrease from ¥589.84 million, reflecting a decline of about 8%[30] Shareholder Information - The total number of common shareholders at the end of the reporting period is 20,651[11] - The largest shareholder, Bao Jianhua, holds 20.12% of shares, totaling 108,399,908 shares, with 59,850,000 shares pledged[11] - The second-largest shareholder, Yu Wenjun, holds 2.45% of shares, totaling 13,216,446 shares[11] - The total number of restricted shares at the end of the period is 97,806,247, with 2,574,362 shares released during the period[14] - The company has a total of 99,439,568 restricted shares at the beginning of the period[14] - The top ten shareholders collectively hold significant stakes, with the largest holding being over 20%[11] - The total number of shares held by the top ten unrestricted shareholders is 69,000,000[12] - The company has a diverse shareholder base, including both individual and institutional investors[11] - There are no changes reported in the lending or borrowing of shares among the top shareholders[12] - The company has a strategy for unlocking 25% of restricted shares annually based on the previous year's holdings[14] Business Development - The company established WeiRan International Industrial Co., Ltd. in Singapore and WeiRan Business Alliance (Shanghai) Food Technology Co., Ltd. in Shanghai to expand its international business in new protein[15] - The company has received a fertilizer registration certificate for its amino acid water-soluble fertilizer, allowing it to be marketed domestically, which is expected to become a new profit growth point[17] - The company obtained a Korean invention patent for the application of short-handled Fusarium in producing mycelium protein, enhancing its core competitiveness in the international market[18] Operating Costs and Expenses - Total operating costs for the current period were approximately ¥862.33 million, a decrease from ¥1,077.53 million in the previous period, representing a reduction of about 20%[25] - Research and development expenses were approximately ¥44.10 million, down from ¥54.88 million, indicating a reduction of about 19.5%[25] - The company reported a decrease in sales revenue from services, with cash received from sales amounting to ¥572.72 million, down from ¥694.55 million, a decline of approximately 17.5%[28] Investment Activities - The company experienced a 46.47% increase in cash outflows from investing activities, totaling -¥192,721,538.58[9] - The company recorded a 259.60% increase in non-operating income, amounting to ¥1,379,336.30, due to increased disposal of scrapped assets[9]

Group 1 - The artificial meat concept sector rose by 1.81%, ranking fifth among concept sectors, with 14 stocks increasing in value, including Shuangta Food, which hit the daily limit, and others like Suobao Protein and Haoxiangni showing gains of 6.33%, 3.53%, and 2.66% respectively [1][2] - The main inflow of funds into the artificial meat concept sector was 132 million yuan, with Shuangta Food receiving the highest net inflow of 98.69 million yuan, followed by Suobao Protein and Meiyingsen with net inflows of 46.11 million yuan and 16.86 million yuan respectively [2][3] - The net inflow ratios for Shuangta Food, Suobao Protein, and Meiyingsen were 31.69%, 11.94%, and 8.56% respectively, indicating strong investor interest in these stocks [3] Group 2 - Among the stocks in the artificial meat sector, the top performers included Shuangta Food with a daily increase of 9.98% and a turnover rate of 4.40%, while stocks like Haoxiangni and Dongbao Biological also showed positive performance with increases of 3.53% and 2.66% respectively [3][4] - Conversely, stocks such as Angel Yeast, Fuxiang Pharmaceutical, and Tangrenshen experienced declines of 0.91%, 0.57%, and 0.21% respectively, indicating mixed performance within the sector [1][4]

Core Viewpoint - Fuxiang Pharmaceutical has recently obtained an invention patent certificate from the Korean Intellectual Property Office for the application of "short-stemmed fusarium in the production of mycelial protein" [2] Company Summary - The patent awarded to Fuxiang Pharmaceutical is significant as it highlights the company's innovation in utilizing short-stemmed fusarium for producing mycelial protein, which may enhance its product offerings and competitive edge in the pharmaceutical industry [2]